| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.067 | 0.1 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |